Soleil Boughton Sells 4,915 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 4,915 shares of the company’s stock in a transaction dated Monday, May 20th. The shares were sold at an average price of $20.01, for a total value of $98,349.15. Following the completion of the transaction, the insider now owns 159,357 shares in the company, valued at approximately $3,188,733.57. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Soleil Boughton also recently made the following trade(s):

• On Monday, May 13th, Soleil Boughton sold 2,503 shares of Hims & Hers Health stock. The shares were sold at an average price of $12.33, for a total transaction of $30,861.99.
• On Monday, April 29th, Soleil Boughton sold 2,503 shares of Hims & Hers Health stock. The stock was sold at an average price of $12.56, for a total transaction of $31,437.68.
• On Monday, April 15th, Soleil Boughton sold 2,503 shares of Hims & Hers Health stock. The shares were sold at an average price of $13.95, for a total transaction of $34,916.85.
• On Monday, April 1st, Soleil Boughton sold 2,503 shares of Hims & Hers Health stock. The shares were sold at an average price of $15.65, for a total value of $39,171.95.
• On Wednesday, March 13th, Soleil Boughton sold 63,621 shares of Hims & Hers Health stock. The shares were sold at an average price of $15.17, for a total value of $965,130.57.

Hims & Hers Health Stock Down 7.9 %

HIMS opened at $16.18 on Thursday. The firm’s 50-day simple moving average is $14.08 and its 200-day simple moving average is $11.01. Hims & Hers Health, Inc. has a twelve month low of $5.65 and a twelve month high of $20.11.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, May 6th. The company reported $0.05 EPS for the quarter, beating the consensus estimate of $0.02 by $0.03. Hims & Hers Health had a negative net margin of 0.24% and a negative return on equity of 0.70%. The business had revenue of $278.20 million for the quarter, compared to analysts’ expectations of $270.37 million. During the same period in the prior year, the firm earned ($0.05) earnings per share. Hims & Hers Health’s revenue was up 45.8% compared to the same quarter last year. Equities analysts expect that Hims & Hers Health, Inc. will post 0.18 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have commented on HIMS shares. Citigroup downgraded shares of Hims & Hers Health from a “buy” rating to a “neutral” rating and boosted their target price for the stock from $16.00 to $20.00 in a research report on Wednesday. Canaccord Genuity Group assumed coverage on shares of Hims & Hers Health in a research report on Wednesday, April 10th. They set a “buy” rating and a $20.00 target price on the stock. Imperial Capital raised shares of Hims & Hers Health from an “in-line” rating to an “outperform” rating and set a $16.00 price target on the stock in a research report on Wednesday, February 28th. Canaccord Genuity Group raised their target price on shares of Hims & Hers Health from $20.00 to $24.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, Seaport Res Ptn reissued a “buy” rating on shares of Hims & Hers Health in a research report on Friday, April 26th. Seven equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $15.69.

Institutional Trading of Hims & Hers Health

A number of institutional investors have recently bought and sold shares of HIMS. Virtu Financial LLC bought a new position in Hims & Hers Health during the first quarter worth about $638,000. Strategic Wealth Partners Ltd. bought a new stake in Hims & Hers Health in the first quarter valued at approximately $839,000. Bayesian Capital Management LP acquired a new stake in Hims & Hers Health in the first quarter worth $1,770,000. SVB Wealth LLC bought a new position in shares of Hims & Hers Health during the first quarter worth $421,000. Finally, Price T Rowe Associates Inc. MD grew its holdings in shares of Hims & Hers Health by 239.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 168,427 shares of the company’s stock valued at $2,606,000 after buying an additional 118,848 shares during the period. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.